SURROZEN, INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________Preferred Stock Warrant Agreement • December 9th, 2022 • Surrozen, Inc./De • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 9th, 2022 Company Industry JurisdictionTHIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SURROZEN, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
SURROZEN, INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • December 9th, 2022 • Surrozen, Inc./De • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 9th, 2022 Company Industry JurisdictionTHIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SURROZEN, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
SURROZEN, INC. AND _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • December 9th, 2022 • Surrozen, Inc./De • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 9th, 2022 Company Industry JurisdictionTHIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between SURROZEN, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
SURROZEN, INC. SALES AGREEMENTSales Agreement • December 9th, 2022 • Surrozen, Inc./De • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 9th, 2022 Company Industry JurisdictionAs further set forth in this agreement (this “Agreement”), Surrozen, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Guggenheim Securities, LLC (the “Agent”), as sales agent, shares of the Company’s common stock (the “Shares”), par value $0.0001 per share (the “Common Stock”) up to such number or dollar amount as is equal to the Maximum Amount (as defined below). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of shares of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.